<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104350</url>
  </required_header>
  <id_info>
    <org_study_id>10-031</org_study_id>
    <nct_id>NCT01104350</nct_id>
  </id_info>
  <brief_title>Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy</brief_title>
  <official_title>Phase I Dose-Escalation Study of Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of different amounts (doses) of external
      radiation therapy (high-energy x-rays that shrink or destroy cancer) combined with
      chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the dose limiting toxicity and establish the maximal tolerated dose</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the complete response rate of the primary tumor</measure>
    <time_frame>4-6 weeks following consolidation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the long term toxicity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy and Concurrent Gemcitabine Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a Phase I dose-escalation study examining the safety and tolerability of intensity modulated external radiation therapy using image-guidance in combination with gemcitabine chemotherapy as an alternative to radical cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>external radiation therapy with gemcitabine</intervention_name>
    <description>All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.
Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)
Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)
Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)</description>
    <arm_group_label>Radiotherapy and Concurrent Gemcitabine Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MSKCC-reviewed pathologically proven diagnosis of primary bladder urothelial carcinoma
             without evidence of regional (nodal) or distant spread (cT1-T4a, Nx or N0).

          -  Karnofsky Performance Scale (KPS) ≥ 70%

          -  Age ≥18 years old

          -  Adequately functioning bladder, defined as continent and without the need for an
             indwelling catheter

          -  Absolute neutrophil count (ANC) ≥ 1500/mL; platelets ≥ 100,000/mm3 serum bilirubin &lt;
             1.5 x the upper limit of normal (ULN); aspartate aminotransferase (AST) and/alanine
             aminotransferase (ALT) ≤ 1.5 × ULN

          -  Adequate renal function: calculated creatinine clearance &gt; 30 mL/min/1.73 m2 using the
             following formula modified Cockcroft and Gault Formula for estimated Creatinine
             Clearance

          -  Patients must be considered able to tolerate systemic chemotherapy and pelvic
             radiation therapy.

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent document

        Exclusion Criteria:

          -  Evidence of distant disease or histologically-proven nodal metastases. Patients with
             radiologic evidence of lymphadenopathy must have biopsy proof of N0 status.

          -  Previous pelvic radiation therapy

          -  Prior systemic chemotherapy non-cisplatin based neoadjuvant for urothelial carcinoma
             (prior intravesical chemotherapy or immunotherapy is permissible)

          -  Prior cisplatin based neoadjuvant systemic chemotherapy for more than &gt;4 cycles

          -  Active inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis)

          -  Women who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marisa Kollmeier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>10-031</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

